This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

The present invention provides a particulate delivery device with an automatic activation mechanism that pierces or cuts a composition capsule when a cap is removed. The cap cannot be replaced once the device is activated for use. The device allows for gas flow through the device from a gas inlet to a gas outlet through a composition receptacle and dispersion chamber to deliver particulate to the airway of a subject.

A dry powder inhaler (1) has a chamber (12) for housing a capsule and an inhalation channel (22), the chamber (12) is shaped in order to determine an agitated motion of the capsule in the chamber (12) during an inhalation of a user, the inhaler (1) comprises a capsule-piercing mechanism (30) arranged to pierce a capsule in the chamber (12) and a monitoring system (40) comprising an accelerometer (42) arranged on a printed circuit board (48) in order to measure mechanical oscillations determined at least by the agitated motion and by a flow of air through the chamber (12) and/or inhalation channel (22); a detection unit (44) arranged to detect an activation of the capsule-piercing mechanism (30); and an electronic processing unit (46) configured to receive signals from the detection unit (44) and from the accelerometer (42). Reception of a signal from the detection unit (44) triggers processing of signals from the accelerometer (42) by the electronic processing unit (46) in order to generate inhalation data.

Methods and devices for delivering a dose, such as a medicament, for inhalation. A dose may be stored by a delivery device and dispersed and delivered in a metered fashion to a subject, such as by the subject inhaling via a mouthpiece of the delivery device. One or more chambers of the device may have a toroidal shape and may be arranged to be selectively opened for fluid communication with a flow path of the delivery device, such as by sliding the chamber relative to a portion of the flow path. The flow path may include a restriction that permits air to bypass the chamber, and/or the chamber may be arranged so that fluid entering the chamber interacts with fluid exiting the chamber so as to enhance dispersion of the dose.

An example aerosol delivery device includes a mouthpiece having an airflow outlet, and an airflow passage extending between an airflow inlet and the airflow outlet. The example aerosol delivery device further includes a housing configured to receive a cartridge that includes an aerosolizable substance and a vapor element configured to heat the aerosolizable substance, and an internal power source configured to provide electrical power. The example aerosol delivery device further includes a controller coupled to the internal power source to receive a portion of the electrical power and configured to, when the cartridge is installed at the housing, cause the vapor element of the cartridge to heat the aerosolizable substance to release an aerosol into the airflow passage during an inhalation through the airflow outlet, and a connector configured to receive power from an external source to recharge the internal power source.

The present invention provides a dry powder inhaler comprising: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; and a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, wherein the formulation comprises an inhalable β.sub.2-agonist having a particle size distribution of d1O<1 μπ.Math.=1-3 μπ.Math., d90=3.5-6 μm and NLT 99% 10 μm and a lactose carrier.

A nicotine powder delivery system includes an inhaler article and a nicotine powder capsule disposed within the inhaler article. The nicotine powder capsule rotates about a longitudinal axis when air flows through the inhaler article.

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

An apparatus includes a first member coupled to a second member. The first member defines a chamber containing a dry powder and includes a chamber wall that forms an outer boundary of the chamber. The second member includes a surface covering the chamber and defines an intake channel and an exit channel. The exit channel is fluidically coupled to the chamber via an exit opening. The intake channel is fluidically coupled to the chamber via an intake port. A center line of the intake channel is tangential to a portion of the chamber wall such that a portion of an inlet airflow conveyed into the chamber via the intake channel has a rotational motion. The intake port is defined at least in part by an intake ramp. The intake ramp includes a transition surface that forms an exit angle with respect to the surface of less than 105 degrees.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.